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Application of response surface methodology to 
maximize the productivity of scalable automated 
human embryonic stem cell manufacture
During recent years, there has been significant 
progress in the development of human cell-based 
therapies to treat a wide range of disease states 
[1]. Regenerative medicine (RM) approaches use 
such cells to repair or replace damaged or diseased 
human cells, tissues or organs in order to restore 
normal function [2]. The large number of RM cell 
products in preclinical or clinical development 
support projections for the development of a 
multibillion dollar industry over the coming 
decade, with long-term public health benefits 
[3]. However, manufacturing of cell therapies 
is complex and many face problems achieving 
the transition from the laboratory bench-scale 
to robust manufacturing-scale processes with 
consistent quality and commercially viable costs 
[4]. Much of this is due to a lack of economic 
and controllable manufacturing platforms for 
adherent cell production, poor definition of 
the critical process parameters that impact cell 
product quality and the difficulty of defining 
the quality of biological input materials; this is 
compounded by a product that is highly sensitive 
to changes in the production environment. 
Purification or enrichment of the end product to 
deal with process variability increases costs and 
is restricted relative to biomolecular therapies 
where the final product is distinct from the 
bioprocessed cells [5]. Many candidate cell-based 
therapy bioprocesses are therefore considered to 
be high risk with significant end-point testing 
and failure rates. 
Other complex manufacturing industries 
have applied multivariate designs of experiments 
within a systematic framework to address similar 
process optimization and control issues [6,7]. 
These experimental designs provide empirical 
models that predict the response of critical process 
outputs to the levels of multiple input variables. 
Depending on the process response targeted, 
such process characterization can reduce risk by 
defining critical parameter operating windows 
and indicate opportunities to increase process 
efficiency or product quality. Compared with 
conventional ‘one factor at a time’ experimental 
approaches, they define interdependent effects 
of process inputs on process responses (prevalent 
in biomanufacture systems) and are highly 
efficient in terms of data output per experimental 
condition [7,8]. However, the complexity of cell 
culture bioprocesses and the confounding of 
input variable effects over time make them hard 
to model as a single unit. Design of experiments 
approaches can address this through focusing 
on subprocess units; a sequence of controlled 
subprocesses, or units of manufacture, will 
generate a controlled, continuous process. 
Systematic application of these methods needs 
to become routine in order to enable data-driven 
decision-making to improve RM process outputs 
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that are critical to product quality and support 
risk-based approaches to manufacture. However, 
only early examples of practical applications, and 
the issues with these examples, are currently 
emerging in RM [9].
Human embryonic stem cells (hESCs) are of 
significant importance as a renewable source of 
cells for RM applications due to their ability to 
self-renew and differentiate into any cell type 
[10]. The generation of large numbers of cells for 
prospective therapies and hESC maintenance 
is labor intensive; for example, it is estimated 
that in excess of 109 hESCs would be required 
to generate enough cardiomyocytes to repair 
an infarcted heart [11]. To address this issue, we 
previously developed a fully automated robotic 
process, using the CompacT SelecT™ platform 
(TAP Biosystems, UK; with a previously 
reported single-cell suspension passage method 
[12]), to provide proof of principle that highly 
controlled automated production of 109 hESCs 
is feasible [13].
We have used a modification of this scalable 
and automatable method of cell culture with 
defined mTeSR1 media to optimize and validate 
a single manufacturing subprocess (between 
two passages) for cost and quality. Cost is an 
important target because, unlike conventional 
small-molecule pharmaceuticals, cell-based 
product manufacture defines a significant 
proportion of cost of goods supplied and therefore 
commercial viability [3]. We selected media 
volume, media change frequency, cell seeding 
density and time between passage as significant 
determinants of process cost. We employed a 
response surface method (RSM) experimental 
design, which is a high-resolution method 
capable of modeling nonlinear relationships, 
to model the effects of these variables between 
two passages (the subprocess) on cell yield. We 
also modeled the effects of the input variables 
on the recovery of the cells after experimental 
conditions were applied (assessed by population 
doublings in 24 h postpassage) because of reports 
of cell death and poor recovery after single-cell 
passage methods [14]. This enabled validation of 
an RSM predicted economic production strategy 
for an industrially relevant and scalable hESC 
culture process.
Materials & methods
n Materials & general culture
All tissue culture reagents were purchased 
from Invitrogen (UK), plastic ware from 
Fisher Scientific (UK) and chemicals from 
Sigma-Aldrich (UK), unless otherwise stated. 
All work processes were controlled by a set 
of detailed standard operating procedures to 
minimize background variability, and laboratory 
environmental conditions were monitored (i.e., 
temperature) to ensure no deviations occurred 
that could impact the data.
n hESC culture
To ensure experimentation was economic, 
but that results would be scalable in line with 
previously described automated protocols, we 
designed a low-scale T25-based manual pro-
cess with direct step-by-step equivalence to 
the automated and scalable T175-based single-
cell suspension passage method previously 
reported [13]. Specifically, the hESC line, H9 
(WiCell Research Institute, WI, USA), was 
cultured in feeder-free conditions on growth 
factor-reduced hESC-qualif ied Matrigel™ 
(BD Biosciences, UK) in mTeSR1 medium 
(StemCell Technologies, France). Cells were 
thawed at passage 35 and passaged three 
times (under central point conditions; refer 
to Table 1) prior to experimental intervention. 
Cultures were maintained at 37°C, 5% CO
2
 in 
a humidified atmosphere with medium change 
every 24 h and passaged every 48 h unless other-
wise stated. Matrigel was used to coat 25-cm2 
Corning tissue culture flasks (T25s) according 
to manufacturer’s instructions by dilution in 
cold DMEM-F12, allowing polymerization to 
occur at 22°C for 45 min. Prior to use, medium 
was aspirated from flasks and the culture surface 
washed with phosphate-buffered saline. Culture 
passage was performed by incubation with 5 ml 
TrypLE™ SelecT (Life Technologies, NY, 
USA) for 3 min at 37°C, coupled with shak-
ing the flasks to liberate single cells and small 
cell aggregates, and trituration of warm (37°C) 
mTeSR1 across the flask surface was carried out 
to generate cell pools for analysis and further 
culture seeding. Cultures were initiated at sev-
eral cell seeding densities and medium volumes 
(as detailed in Table 1; viability: 98.80 ± 0.18%; 
µ ± s, n = 3). 
n hESC analysis
Cell pool density and viability assessment 
was performed using the automated Innovatis 
Cedex™ Analyzer (Roche Diagnostics Ltd, 
UK) and the trypan blue dye exclusion method 
(Roche Diagnostics Ltd). The equation log
10
(cell 
output/cell input)/log
10
2 was used to calculate 
population doublings of cultures. Flow cytometry 
for hESC pluripotency and early differentiation 
markers was performed using a Cell Lab 
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Quanta™ SC Flow Cytometer (Beckman 
Coulter, UK) and the following conjugated 
antibodies and appropriate isotype controls 
according to manufacturer’s instructions; Oct4a-
phycoerythrin (PE), SSEA1-PE, SSEA4-PE, 
alkaline phosphatase-PE (R&D Systems, UK), 
SSEA3-PE, Tra-1-81-PE and Nanog-PE (BD 
Biosciences, UK). Data presented are the means 
and standard deviations of percentage marker 
expression for triplicate samples (µ ± s, n = 3).
n RSM design & analysis
A three-level, three-factor (i.e., 33) Box–Behnken 
experimental design was applied to evaluate the 
effects of three factors – seeding density (X
SD
), 
media volume (X
MV
) and media exchange time 
(X
FT
) – in the period between two consecutive 
passages. hESC expansion performance at the 
second passage, and 24 h thereafter (harvest), 
were analyzed as response variables (Y
1
 and Y
2
, 
respectively). This design studied the combined 
effects of the three factors in a single block of 
12 sets of test conditions, augmented with five 
central points to estimate pure error. Three 
levels were attributed to each factor, coded as 
low (-1), medium (0) and high (+1) (Table 1). 
The order of the experiments was fully random-
ized. Additionally, the RSM study considered 
process time as a fourth factor, by applying the 
33 Box–Behnken design across three levels of 
duration between the first and second passage 
(standard every 48 h). 
Statistical analysis was performed with the 
software package Design Expert®, version 8.0.5 
(Stat-Ease, Inc., MN, USA). Analysis of variance 
was applied to establish a prediction model 
for each response. The selected models were 
evaluated according to a battery of adequacy 
tests and graphical analysis was carried out as 
previously described [15], and in brief below. 
Each fitted model was examined to ensure that 
it provides an adequate approximation to the 
true system in order to empirically assess the 
usefulness of the predictive capabilities of the 
model and to verify that the model satisfies the 
assumptions of the analysis of variance. 
In brief, the regression model diagnostics for 
reported models were within acceptable limits 
(summary statistics are shown in Tables 2 & 3). 
Lack-of-fit tests were not significant, indicat-
ing that additional variation in the residuals 
could not be removed with a better model. The 
linear correlation plots between the actual and 
Table 1. Standard and response surface method experimental 
culture conditions.
Factors Levels
Low (-1) Medium (0) High (+1)
X
SD
 (106 cells) 1.50 2.50† 3.50
X
MV
 (ml) 5.00 8.75† 12.50
X
FT
 (h) 24 24 + 50%† 24 + 100%
Process time (h) 36 48† 60
Thirteen factorial combinations of these culture parameter levels, specified by the response surface 
method experimental design software, were conducted on experimental laboratory cultures to 
generate the data for the process models. Because culture duration was different for each of the three 
response surface method experiments, the time of media exchange is not specified as an absolute 
value in the table. Media exchange occurred at 24 h, halfway between 24 h and the end of the culture 
period (specified as 24 + 50%) or there was no media exchange (specified as 24 + 100%). The 
absolute time value of the exchange therefore varied depending on the length of the culture period.
†Central point culture conditions.
X
FT
: Media exchange time; X
MV
: Media volume; X
SD
: Seeding density (T25 flask).
Table 2. A reduced two-factor interaction model that describes the response 
surface for the process response passage yield.
Source Sum of squares df Mean square F value p-value
Model 65.63 3 21.88 37.38 <0.0001
X
SD
61.94 1 61.94 105.84 <0.0001
X
MV
0.66 1 0.66 1.13 0.3071
X
SD
X
MV
3.03 1 3.03 5.17 0.0405
Residual 7.61 13 0.59 – –
Lack of fit 6.74 9 0.75 3.44 0.1229
Pure error 0.87 4 0.22 – –
Cor total 73.23 16 – – –
The experimental data were used to generate theoretical models of process performance around the experimental levels 
run in the laboratory. The table shows a summary of the analysis of variance data and model statistics. 
Standard deviation: 0.76; mean: 6.56; CV: 11.67; PRESS: 16.05; R2: 0.8961; Adj R2: 0.8721; Pred R2: 0.7809; 
Adeq precision: 19.686.
Adeq precision: Signal-to-noise ratio; Adj R2: Amount of variation around the mean explained by the model, adjusted for 
the number of terms in the model; Cor total: Corrected total of all information corrected for the mean; CV: Coefficient of 
variation; df: Degrees of freedom; F: Fischer’s variance ratio; Pred R2: Amount of variation in new data explained by the 
model; PRESS: Predicted residual error sum of squares; R2: Amount of variation around the mean explained by the model; 
X
MV
: Media volume; X
SD
: Seeding density.
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predicted response variables indicate coefficient 
of determination values close to 1, confirming 
high predictive power for both models and a 
good fit between the model and the experimen-
tal data. The close agreement between the three 
coefficient of determination statistics indicates 
that there is good agreement between the experi-
mental and predicted values for both responses. 
The precision of both models indicates that 
the signal-to-noise ratio of the data is adequate 
(>4) and confirms that the models can be used 
to navigate the design space. The coefficient of 
variation for both responses is low, indicating 
close agreement between repeat measurements. 
Graphical residual and influence diagnostics 
were also conducted for the reported models and 
were within acceptable limits. Graphical plots 
were of internally studentized residuals versus: 
the predicted responses, showing random scatter 
and absence of trends, confirming constant 
variance; the experimental run order, showing 
random scatter, indicating the absence of sources 
of nonrandom error or lurking variables; or the 
individual factors, showing random scatter, 
indicating absence of curvature or significant 
differences in the magnitude of residuals 
between levels. The predicted versus measured 
response plots showed close correlation between 
the modeled and measured data points. 
Graphical plots of the externally studentized 
residuals and Cook’s distance versus the 
experimental run order did not detect any data 
points that could be considered to be outliers 
or otherwise unusual/suspect. The DFFITS and 
DFBETAS plots did not indicate any treatments 
with overly large influences on predictions or 
regression coefficients.
Results
n Unit of manufacture
A standard 8-day cell expansion process from an 
H9 hESC cryobank was developed as an experi-
mental unit of manufacture for application of the 
RSM tool. Prior to applying the RSM experimen-
tal conditions, the unit of manufacture was repeat-
edly performed under standard operating condi-
tions to provide evidence of statistical control of 
the process, confirm hESC pluripotency marker 
expression (Figure 1) and to verify the performance 
of the measurement systems. Upon defrost, mean 
viable cell recovery was 5.5 × 106 ± 0.3 (µ ± s, 
n = 3) and average viability was 98 ± 0.3% (µ ± s, 
n = 3). At day 6 of the process, which was the 
point of the subsequent RSM experiment, aver-
age viable cell yield was 67.2 × 106 ± 0.3 (µ ± s, 
n = 3; 3.6 population doublings) and average 
viability was 99.5 ± 0.3% (µ ± s, n = 3), which 
is equivalent to early expansion levels that have 
Table 3. A two-factor interaction model that describes the response surface for the 
process response: cell culture recovery after passage (population doublings in 24 h 
after experimental conditions)†.
Source Sum of squares df Mean square F value p-value
Model 127.95 6 21.33 39.35 <0.0001
X
SD
33.73 1 33.73 62.25 <0.0001
X
MV
35.91 1 35.91 66.26 <0.0001
X
FT
13.14 1 13.14 24.25 0.0006
X
SD
X
MV
28.85 1 28.85 53.23 <0.0001
X
SD
X
FT
3.16 1 3.16 5.84 0.0363
X
MV
X
FT
13.16 1 13.16 24.29 0.0006
Residual 5.42 10 0.54 – –
Lack of fit 3.90 6 0.65 1.71 0.3146
Pure error 1.52 4 0.38 – –
Cor total 133.37 16 – – –
The experimental data were used to generate theoretical models of process performance around the experimental levels 
run in the laboratory. The table shows a summary of the analysis of variance data and model statistics. 
Standard deviation: 0.74; mean: 6.69; CV: 11.01; PRESS: 18.22; R2: 0.9594; Adj R2: 0.9350; Pred R2: 0.8634; 
Adeq precision: 20.340. 
†The data were transformed to achieve an appropriate distribution characteristic for modeling (transformation: 
power l: 2.11; constant: 2.4497).
Adeq precision: Signal-to-noise ratio; Adj R2: Amount of variation around the mean explained by the model, adjusted for 
the number of terms in the model; Cor total: Corrected total of all information corrected for the mean; CV: Coefficient of 
variation; df: Degrees of freedom; F: Fischer’s variance ratio; Pred R2: Amount of variation in new data explained by the 
model; PRESS: Predicted residual error sum of squares; R2: Amount of variation around the mean explained by the model; 
X
FT
: Media exchange time; X
MV
: Media volume; X
SD
: Seeding density.
RSM application for optimization of hESC manufacture Preliminary CommuniCation
www.futuremedicine.com 43future science group
been previously seen with the automated single-
cell suspension passage method [13]. All cells 
showed typical monolayer hESC morphology, 
high expression levels of pluri potency indica-
tors and low expression levels of differentiation 
indicators, as shown in Figure 1B & 1C.
The objective of the RSM experiment was to 
reduce the cost of the unit of manufacture while 
maintaining or increasing cell product quality 
through targeting a reduction in process time 
and the use of expensive raw materials. A series 
of RSM cell culture experiments was therefore 
designed to minimize process time, cell culture 
liquid volumes and input cell numbers through 
optimization of the process parameters (factors) 
of X
MV
, media exchange schedule (X
FT
) and X
SD
. 
Experimental data were used to model two-
process responses: the yield of the cells from 
the experimental runs (cell yield [Y
1
]) and the 
ability of the cells to proliferate in the passage 
period after exposure to the conditions of the 
experimental run (population doublings at 24-h 
harvest postexperiment [Y
2
]).
n Model selection
Initially, three Box–Behnken RSM cell culture 
experiments, incorporating the chosen factors at 
software-specified design levels, were conducted 
over 36-, 48- and 60-h passage periods (Table 1). 
The experimental data were initially used to 
model the cell recovery after the experimental 
passage (response variable Y
2
, assessed by cell 
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Figure 1. Baseline performance of the bioprocess used for the response surface method 
experimental designs. (A) Repeated processing of the unit of manufacture of human embryonic 
stem cells under central conditions (Table 1) over the experimental period and under strict operating 
procedures showed stable average cumulative population doublings over time (µ ± s, n = 3). 
(B & C) After 6 days of expansion, at the point of experimental intervention, cells showed typical 
morphology, high viability and normal pluripotency marker expression levels. 
Scale bar: 60 µm. 
RSM: Response surface method.
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proliferation over the 24-h postexperimental 
run). This was to exclude conditions that pro-
hibited cell recovery postpassage due to the com-
mon recognition of this issue with single-cell 
passage methods [14]. Analysis of the models with 
a 48- and 60-h passage period did not provide 
outcomes that met critical optimization criteria. 
The 48-h model could not meet the threshold 
criteria of sufficient recovery in the 24-h post-
experimental condition period (minimum speci-
fied as ≤0.2 population doublings). The 60-h 
model did not give a large enough advantage in 
cell yield to offset the projected cost of near dou-
bling of the culture time. Therefore, the 36-h 
model was selected for further analysis.
n Modeling the effects
The design software was used to establish the 
best model to fit the cell culture experimental 
data. The 36-h model Y
1
 and Y
2
 were both best 
predicted by a reduced first-order model with 
interaction. The Y
2
 response required a power 
transformation. Attempts at model reduction by 
backward elimination of nonsignificant terms 
resulted in extremely minor improvements in 
the model for Y
2
 and, therefore, all model terms 
were included in the analysis of variance.
Both of the overall models reported were 
highly significant (p < 0.0001), indicating sig-
nificant factor effects and that the models can 
be considered to be of sufficient quality to navi-
gate the experimental design space and to predict 
new observations. The analysis of variance and 
model statistics confirmed the adequacy of the 
models and revealed significant model terms and 
coefficient estimates that describe the response 
surface for both Y
1
 and Y
2
 as a function of the 
factor settings (Tables 2 & 3). The final predictive 
model equations in terms of the actual factors 
(rounded) were:
and
n Biomanufacture significance
The model that describes the Y
1
 response surface 
was simpler than that describing the Y
2
 response 
surface. It showed a significant linear effect of 
X
SD
 and X
MV
, with no significant effect of X
FT
. 
There was also a significant interaction between 
these two factors: the increase in Y
1
 generated by 
an increased X
SD
 is greater given a higher X
MV
. 
This effect can be visualized in Figure 2, where it 
is shown only for one level of media exchange (as 
media exchange does not affect the process yield 
in this model). The practical significance of this is 
that, within the range of the model, to maximize 
the passage yield, the X
SD
 needs to be balanced 
with the X
MV
. Both high-density, low-volume and 
low-density, high-volume conditions only result 
in a twofold Y
1
 over input, whereas high-density, 
high-volume and low-density, low-volume condi-
tions both give an approximatly threefold Y
1
 over 
the same period. Mechanistically, this suggests 
a requirement to balance nutrient supply with 
concentrations of cell-secreted factors. It sug-
gests that biomanufacture equipment that enables 
continual feed strategies may offer increased cell 
productivity with respect to time.
The model for Y
2
 showed significant linear 
effects of all three factors and also significant 
interactions between all factors. The behavior 
of the response as a function of the factor set-
tings can be visualized graphically with the aid 
of response surface plots and a cube plot (Figure 3). 
Similarly to the Y
1
 model, these interactions have 
practical significance. Figure 3A shows that the 
cells will only recover quickly from low-media-
volume conditions in the experimental passage 
period if they have also had a low X
SD
 and X
FT
 
(the former having more impact than the latter). 
Figure 3B shows that when the X
SD
 is at a low value, 
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the cells recover relatively well after the experi-
ment, irrespective of the other parameter values. 
Figure 3C shows two regions of maximum response 
when the X
FT
 is set at a high value (i.e., mid-
process); there is substantially greater cell recov-
ery after an experimental run with low media 
levels combined with low X
SD
 or with high media 
levels and high X
SD
 (the former having greater 
effect). The low media and cell input condition 
is preferable based on cost-optimization criteria. 
Figure 3D shows the experimental value achieved 
for each run condition that was used to generate 
the process model.
The cell recovery model predicts that high-
yield conditions (Y
1
) do not simply correlate with 
low subsequent cell growth, so the effects on 
postexperiment recovery are not simply mediated 
by the cell density reached in the experimental 
period. It also indicates that a very high rate of 
recovery of cells can be achieved after a single-
cell suspension passage method, but that this 
recovery is very sensitive to the preceding culture 
conditions. This is of particular interest given 
the number of chemical mediators (i.e., ROCK 
inhibitors) currently being investigated to 
overcome the problem of cell death post-single-
cell passage [16]. The variables investigated are 
clearly key determinants of this outcome and 
indicate that a full characterization of the process 
design space for simple bioprocessing parameters 
may be able to change process outcomes as 
effectively as further chemical modifications of 
the culture milieu. The model is consistent with 
the conclusion that when the cell cultures fall 
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Figure 3. Response surface charts of process models. (A) 3D response surface plots for cell recovery (Y
2
; note axis transformed) 
after experimental conditions as a function of X
SD
 and X
FT
 with X
MV
 set at the low-level value (5 ml). Optimal cell recovery is clearly 
achieved after experimental conditions with low X
SD
 and early media exchange. (B) X
MV
 and X
FT
 with X
SD
 set at the low-level value. Y
2
 is 
relatively insensitive to other factors (performing well) when X
SD
 was low in the experimental period. (C) X
SD
 and X
MV
 with X
FT
 set at the 
high-level value (-12; i.e., 24 h). Cell recovery (Y
2
) in the postexperimental period is reduced with either low X
MV
 and high X
SD
, or high X
MV
 
and low X
SD
, indicating a critical balance between nutrient supply and cell factors. (D) A cubic presentation of the Box–Behnken 
experimental design showing experimental cell culture outcomes for run conditions for cell recovery (Y
2
, note transformed data) as a 
function of the three factors: X
SD
, X
MV
 and X
FT
. 
X
FT
: Media exchange time; X
MV
: Media volume; X
SD
: Seeding density; Y
2
: Harvest population doublings (24 h postexperiment population 
doubling).
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beneath a certain threshold of media availability 
per cell, subsequent postpassage recovery will 
be very slow. This could either be because the 
cells are already committed to death, they have 
a prolonged inhibition of proliferation or they 
are more sensitive to the stress of the passage 
process. In any case, it indicates that multivariate 
empirical models such as these are essential to 
achieve both optimal proliferative performances 
over subsequent passages and to achieve process 
robustness. Although primarily critical for 
robust manufacture, this is also an important 
point for experimental scientists where a lack 
of awareness and control of such sensitivity will 
jeopardize the reproducibility of data.
Optimum conditions for the unit of manu-
facture were calculated using the mathematical 
multiple-response optimization routine (desir-
ability analysis) in Design Expert. The design 
specification aimed to achieve maximum yield 
(Y
1
) from the experimental run conditions and 
maximum recovery (Y
2
) in the first 24 h of sub-
sequent culture. Superimposing critical response 
contours generated a graphical optimization dis-
play showing the two regions where these critical 
properties are simultaneously met (Figure 4). The 
model optimization criteria were set to minimize 
X
MV
, media exchange frequency and input cell 
numbers. A lower weighting was given to feed 
frequency due to the capacity of an automated 
system to conduct this step without manual 
labor. The optimization criteria resulted in pre-
dicted optimal factor settings of 2 × 106/T25 cell 
seeding, 6 ml/T25 culture media and a media 
exchange after 24 h. Using the point prediction 
node in Design Expert, the expected responses 
and associated interval estimates were calcu-
lated based on the prediction equation shown 
in the analysis of variance output. Table 4 shows 
the process outputs predicted by the models for 
these process parameters and the actual process 
outputs achieved from a verification cell culture 
run. The average response from the validation 
experiment, comprising three runs at the speci-
fied combination of factors settings, was within 
the bounds of the prediction interval, indicating 
that the prediction represents the true response 
surface. 
Discussion
Creating manufacturing processes that can 
reduce the cost of goods and demonstrate 
robustness to product regulators will be necessary 
for the commercial viability and product 
approval of many cell therapies. The described 
approach is an example of how confidence can 
be built, subprocess by subprocess, into a full 
manufacturing process. This is compatible 
with a ‘quality-by-design’ approach to achieve 
scientific understanding of process control, a 
system that is being increasingly encouraged 
by medical product regulators to improve 
the reproducibility of product safety and 
efficacy. As such studies are applied in the 
real manufacturing environment, longer-term 
validation will be required to show stability 
over time and throughout longer processes. 
More knowledge will need to be developed 
regarding the intermediate process parameters 
(and associated monitoring measurements) that 
form the inputs and outputs of the subprocesses 
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Figure 4. Multiple response overlay graph comprising superimposed 
contour plots from each response; passage yield and harvest population 
doubling. Regions that do not fit the optimization criteria are shaded grey. Interval 
estimates are added to the graphical optimization to account for uncertainty in the 
point predictions and impact of uncertainty on achieving process goals. The blue 
region corresponds to where the point estimate meets the criteria requirements, 
but part of an interval estimate does not. The yellow region shows where the entire 
range of all intervals meets the specified criteria and defines window(s) of 
operability, or the 'sweet spot'. 
PI: Prediction interval; X
MV
: Media volume; X
SD
: Seeding density; Y
1
: Passage yield; 
Y
2
: Harvest population doubling.
Table 4. The optimal process performance predicted by the models 
and the corresponding validation data from a cell culture run.
Response Predicted response (95% CI) Actual response 
Y
1
 (×106 cells) 5.27 (3.47–7.08) 5.01 ± 0.35
Y
2
0.43 (0.12–0.71) 0.43 ± 0.13
The model generated from the experimental data predicted new operating conditions to achieve 
optimal response values for Y
1
 and postexperimental conditions for cell recovery (Y
2
; i.e., for 
maximizing these selected responses and reducing process cost). These conditions were: seeding 
density set at 2.0 × 106/T25, media volume set at 6.0 ml/T25 and media exchange set at 24 h (-12). 
The actual response shows that a validation cell culture run conducted in the laboratory fell within 
the predicted range for both of the modeled responses, confirming the utility of the models for 
optimizing process responses. 
Y
1
: Cell yield; Y
2
: Harvest population doublings.
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or units of manufacture that together generate 
a complete system. In this instance, important 
quality factors, such as genetic stability and 
pluripotency markers, were not measured as 
outputs of the model, as meaningful changes 
in such quality would not be expected to develop 
over a single experimental passage period. For 
the purposes of selecting operating conditions 
from these models, we have made an assumption 
that a cell population that recovers faster after 
passage has been less stressed and is more likely 
to retain desirable characteristics in the long 
term. However, as a deeper understanding of 
the parameters that aid the retention of cell 
phenotype or contribute to clinical efficacy 
is developed, this will enable further process 
responses or associated criteria to be incorporated 
into the models.
The conditions in Table 4, validated with 
experimental cell cultures, represent a 31% 
reduction in cell culture media use, a 25% 
reduction in process time and a 20% reduction 
in input cells over the experimental passage 
period relative to the central or standard oper-
ating conditions. Although the validated condi-
tions also deliver a 44% reduction in absolute Y
1
 
per passage relative to the standard process, this 
is compensated by the 0.4 population doublings 
achieved over the first 24 h of the subsequent 
growth period (relative to zero growth under 
central conditions). If we had not modeled this 
‘cell recovery’ response, we would have selected 
criteria for passage conditions that resulted in 
significant cell death in subsequent processing. 
This is an important note of caution for giv-
ing appropriate consideration to key process 
responses before embarking on optimization. 
Although passaging cells at lower density would 
also have a cost overhead in terms of space and 
flask requirements, this added complexity was 
not considered for the purposes of this exercise. 
Such considerations could be accounted for 
by incorporating additional measured outputs 
in the experimental designs and generating 
additional models that must be satisfied by the 
selected process operating parameters. In this 
manner, the methods can be customized for a 
specific production case.
This work was conducted on a single cell line 
as this is representative of the manufacturing 
scenario, which will usually be based on a 
defined single cell line bank. Absolute values 
predicted by the models reported here will be 
highly sensitive to the strict operating controls 
placed on the process (i.e., they are only valid if 
the control environment is specified); a product 
developer can apply a similar methodology to 
specify operating conditions for their banked 
cell line, within their controlled environment, 
to their own quality specification. This is 
parallel to manufacturing in other industries; 
we would not anticipate being able to take 
defined material from one manufacturer (i.e., 
other cell lines/banks) and location through 
another manufacturer’s processes and achieve 
the same output. Therefore, the value here is not 
the precise operating values reported, but the 
evidence that a relatively simple combination of 
control and experimental design can accurately 
predict a chosen aspect of culture performance. 
It is reasonable to anticipate that industrial 
processes will achieve similar benefits from 
using these approaches to model relevant process 
variables for their case-specific critical process 
responses.
Conclusion
This application of RSM design of experiments 
shows that empirical models can be generated 
and used predictively to optimize outputs in a 
particularly challenging and industrially relevant 
human cell culture system, and that they will be 
an increasingly important tool in creating robust 
and economical manufacturing processes for cel-
lular therapies. Systematic design of experiment 
approaches will need to be widely applied to 
design fit-for-purpose manufacturing processes 
and systems for cellular therapies. 
Executive summary
  The effective application of a quality-by-design process development tool – response surface method – to a subprocess of embryonic 
stem cell manufacture is demonstrated.
  Significant reduction in embryonic stem cell manufacturing costs are achieved using a scalable methodology.
  Operating conditions that achieve significant passage yield and rapid cell recovery postpassage without the use of a ROCK inhibitor are 
identified.
  Predicted optimal operating conditions are validated in confirmatory runs.
  Insight is provided into cell sensitivity to manufacturing conditions, the interaction of manufacturing parameters and the consequent 
control required to achieve critical process outputs.
  The necessity of combining multiple models using carefully selected quality outputs for optimization is identified and discussed.
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